Q2 EPS Estimates for UroGen Pharma Lifted by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN) – Research analysts at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for UroGen Pharma in a report issued on Tuesday, May 13th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.75) per share for the quarter, up from their prior forecast of ($0.81). HC Wainwright has a “Buy” rating and a $55.00 price objective on the stock. The consensus estimate for UroGen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma’s Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.44) EPS, Q3 2026 earnings at $0.22 EPS, Q4 2026 earnings at $0.51 EPS and FY2026 earnings at $0.27 EPS.

UroGen Pharma (NASDAQ:URGN) last issued its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million.

Several other brokerages also recently weighed in on URGN. The Goldman Sachs Group decreased their target price on UroGen Pharma from $22.00 to $16.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a research note on Thursday, May 8th. Scotiabank initiated coverage on UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 target price for the company. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 target price for the company. Finally, Guggenheim restated a “buy” rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $32.86.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN opened at $9.87 on Thursday. The business’s 50-day moving average price is $10.66 and its two-hundred day moving average price is $10.95. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a one year low of $8.94 and a one year high of $20.70. The company has a market capitalization of $455.08 million, a P/E ratio of -3.13 and a beta of 0.66.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP raised its position in UroGen Pharma by 1.3% during the fourth quarter. RTW Investments LP now owns 3,834,794 shares of the company’s stock valued at $40,841,000 after purchasing an additional 47,447 shares in the last quarter. Toronto Dominion Bank acquired a new position in UroGen Pharma during the fourth quarter valued at approximately $18,628,000. Vestal Point Capital LP raised its position in UroGen Pharma by 307.5% during the fourth quarter. Vestal Point Capital LP now owns 1,630,000 shares of the company’s stock valued at $17,360,000 after purchasing an additional 1,230,000 shares in the last quarter. Acorn Capital Advisors LLC acquired a new position in UroGen Pharma during the fourth quarter valued at approximately $16,149,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in UroGen Pharma by 2.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,377,156 shares of the company’s stock valued at $14,667,000 after purchasing an additional 36,084 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors and hedge funds.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.